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Tumour progression is regulated by a number of stimulators and
inhibitors of tumour angiogenesis (Folkman, 1995). Among the
angiogenesis stimulators, vascular endothelial growth factor
(VEGF) has been shown to be the most powerful mitogen for
endothelial cells. Among VEGF members, VEGF-C has recently
been found to induce not only angiogenesis but also lymphangio-
genesis via VEGF receptor-2 (VEGFR-2) and VEGF receptor-3
(VEGFR-3) (Mustonen et al, 1995; Cao et al, 1998; Yonekura 
et al, 1999). A few researchers have reported the possible associa-
tion of VEGF-C expression with intratumoural lymphatic vessel
density or lymph node metastasis in some neoplasms (Ohta et al,
1999; Tsurusaki et al, 1999; Yonemura et al, 1999; Akagi et al,
2000; Niki et al, 2000). Of importance, some studies have recently
shown that VEGF-C-mediated tumour lymphangiogenesis
promotes cancer metastasis including nodal metastasis (Mandriota
et al, 2001; Skobe et al, 2001). In the present study, we assessed
the expression of VEGF-C and its receptors to better delineate
their association with lymph node metastasis and cancer progres-
sion in non-small cell lung cancer. 
MATERIALS AND METHODS 
Tissue samples 
Tumour samples were randomly obtained from 62 patients who
had received surgery in the Kanazawa University Hospital
between 1996 and 1997. For the immunohistochemical study,
consecutive 6 mm-thick sections were cut from the tumour margin.
The pathologic classification of each sample was confirmed by a
review of haematoxylin and eosin (H&E)-stained sections. The
pathological types were 36 adenocarcinomas, 20 squamous cell
carcinomas, 2 adenosquamous carcinomas and 4 large cell carci-
nomas. The pathological stages were classified as stage I in 28
patients, II in 7, III in 26 and IV in 1 according to the Japanese
Lung Cancer Society Classification. 
Immunohistochemistry for VEGF-C and VEGFRs 
The primary antibodies used in this study were an anti-VEGF-C
goat polyclonal antibody at 1:200 dilution (Santa Cruz
Biotechnology, Inc, Santa Cruz, CA, USA), an anti-VEGFR-3
rabbit polyclonal antibody at 1:200 dilution (Santa Cruz
Biotechnology, Inc, Santa Cruz, CA, USA), an anti-VEGFR-2
rabbit monoclonal antibody at 1:200 dilution (Santa Cruz
Biotechnology, Inc, Santa Cruz, CA, USA) and an anti-CD34
mouse monoclonal antibody (Nichirei, Tokyo, Japan). Paraffin
sections were deparaffinized and immunohistochemical staining
was performed using the immunoperoxidase technique.
Endogenous peroxidase was blocked by treatment with 0.3%
hydrogen peroxide in methanol for 15 min, and the sections were
washed with Dulbecco’s phosphate-buffered saline (pH 7.2)
without calcium ion or magnesium ion (PBS–). Tissue non-specific
binding sites were blocked by 10% normal rabbit serum for
VEGF-C, and by 10% normal goat serum for VEGFR-2, VEGFR-
3 and CD34 for 15 min at room temperature. After they had been
washed with PBS-, the sections were reacted with antibodies for
16 h at 4°C. Then they were washed with PBS-and reacted with
biotinylated second antibody for 30 min at room temperature.
After they had been washed with PBS-, avidin-biotin-peroxidase
complex (DAKO LSAB2 system, DAKO Co, Carpinteria, CA,
USA) was added and colour was developed using 3-3¢-
diaminobenzidine (Sigma, St Louis, MO, USA) with 0.03%
hydrogen peroxide. Counterstaining was done with haematoxylin.
For the negative control, all reagents except for the primary anti-
body were used. The specificities of VEGF-C and VEGFR-3 were
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Santa Cruz, CA, USA). 
Assessment of microvessel density and
immunohistochemical assessment of VEGF-C, VEGFR-
2, and VEGFR-3 
The total number of vascular endothelial cells was determined by
immunohistochemistry for CD34 (Figure 1). The number was
assessed blindly by 2 investigators. After the areas of highest
vascularization had been chosen under low power (100 ´ magnifi-
cation), vessel count within tumours was carried out in 3 fields on
the screen image which was captured at 200 ´ magnification. The
average counts of the 3 fields were recorded, and the mean value
of the 2 investigators was used for the total number. For evaluation
of immunostainings, cases in which at least 5% of tumour cells
were immunoreactive were defined as being positive. As for the
VEGFR-2 and VEGFR-3 staining within tumour cells, cases in
which more than 50% of tumour cells were immunoreactive were
defined as being strongly positive. As for the VEGFR-2 and
VEGFR-3 staining within endothelial cells, after counting the total
number of endothelial cells by CD34 staining as described above,
the number of VEGFR-2- or VEGFR-3-positive endothelial cells
was determined in the same manner by using consecutive paraffin
sections. Cases in which at least 5% of endothelial cells were
immunoreactive were defined as being positive in this study. 
Western blot analysis of VEGFR-3 in human lung
cancer cell lines 
5 human lung cancer cell lines (PC-3, PC-8, PC-10, PC-14, QG-
56) were used and maintained in RPMI-1640 media (Gibco BRL,
Gaithersburg, MD, USA) supplemented with 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 10 mM HEPES buffer, 500
units ml–1 pencillin and 500 units ml–1 streptomycin at 37°C and
5% CO2. HUVEC was used as a positive control for VEGFR-3 and
maintained in medium 199 (Life Technologies, Grand Island, NY,
USA) supplemented with 20% FBS, 100 mg ml–1 EC growth
supplement, 50 U ml–1 heparin, glutamine and antibiotics. 20 mg of
protein sample were obtained from each cell line and mixed with 6
ml of sample buffer (50 mM Tris-HCL (pH 6.5), 10% glycerol, 2%
SDS, and 0.1% bromphenol blue) prior to separation by 10% sodium
dodecyl sulfate-polyacrylamide gel, followed by electrophotetic
transfer of the proteins to a PVDF membrane (Millipore, Bedford,
MA). The transferred samples were reacted with an anti-
VEGFR-3 polyclonal antibody at 1:1000 dilution (Santa Cruz
Biotechnology, Inc, Santa Cruz, CA, USA) and anti-b-actin mono-
clonal antibody (Sigma Chemical Co, St Louis, MO) for 2 h at
room temperature. Secondary antibody, anti-mouse coupled to
horseradish peroxidase, was incubated with the membrane and
then washed in TBS-T. The presence of secondary antibody bound
to membrane was detected by using the ECL Western blotting
detection reagent (Amersham Life Science, Buckinghamshire,
UK). As a negative control, primary VEGFR-3 antibody, which
was pre-absorbed with the blocking peptide (Santa Cruz
Biotechnology, Inc, Santa Cruz, CA, USA) overnight was used. 
Statistics 
Fisher’s exact test was used to examine the association between
different variables and clinicopathological factors. Survival curves
were obtained using the Kaplan–Meier method and compared
using the log-rank test. A multivariate model using the Cox step-
wise regression analysis was used to evaluate the statistical
strength of independent association between selected covariates
and patient survival. A P value less than 0.05 was considered
significant. 
RESULTS 
VEGF-C, VEGFR-2 and VEGFR-3 expression in lung
cancer tissue 
VEGF-C antigen was observed in the cytoplasm of cancer cells
(Figure 2). No staining was observed in the normal lung tissue.
VEGF-C expression was positive in 38.7% (24/62) of the lung
cancer patients. VEGFR-2 and VEGFR-3 antigens were observed
in the cytoplasm of endothelial cells and cancer cells (Figure 3).
The percentages of patients with positive VEGFRs in endothelial
cells were 64.5% (40/62) for VEGFR-3 and 74.1% (46/62) for
VEGFR-2. The percentages of patients with positive VEGFRs in
cancer cells were 77.4% (48/62) for VEGFR-3 and 100% (62/62)
for VEGFR-2. The percentages of the patients with strongly posi-
tive VEGFR staining in cancer cells were 27.4% (17/62) for
VEGFR-3 and 51.6% (32/62) for VEGFR-2. A significant positive
correlation was found between VEGF-C expression in cancer cells
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Figure 1 Example of immunohistochemical staining for antibody against
CD34. Scale bar, 25 mm 
Figure 2 Immunohistochemical staining for VEGF-C. Cytoplasmic staining
was positive in tumour cells. Scale bar, 50 mm and VEGFR-3 expression in endothelial cells (P < 0.01), but not
between VEGF-C in cancer cells and VEGFR-2 in endothelial
cells (Table 1). Moreover, the expression of VEGF-C in cancer
cells was also significantly associated with the intensities of both
VEGFR-2 and VEGFR-3 staining in cancer cells (both P < 0.05)
(Tables 1, 2). As a result of the Western blot analysis, a Mr 125 000
band corresponding to VEGFR-3 protein was detected in all 5 lung
cancer cell lines used (Figure 4). 
Correlations between VEGF-C expression and
clinicopathological factors 
Table 3 shows the correlations between clinicopathological factors
and VEGF-C expression. VEGF-C expression was more
frequently found in tumours with lymph node metastasis than in
those without it (P < 0.05). VEGF-C expression in tumours with
lymphatic invasion was significantly greater than that in tumours
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Figure 3 Immunohistochemical staining for VEGFR-2 and VEGFR-3. Stainings of VEGFR-2 were identified in the vascular endothelial cells (A) (scale bar,
25 mm) and cytoplasm of tumour cells (B) (scale bar, 50 mm). VEGFR-3 staining was also found in the endothelial cells (C) (scale bar, 25 mm) and cytoplasm
of tumour cells (D) (scale bar, 50 mm) 
Table 1 Correlation between VEGF-C and VEGFR-3 expression 
Expression of  No. of cases No. (%) of cases  P value No. (%) of cases   P value 
VEGF-C with strong positive  with positive
VEGFR-3 (T) VEGFR-3 (EC)
Positive 24 10 (41.6%) 0.045 21 (87.5%) 0.003 
Negative 38 7 (18.4%) 19 (50.0%) 
VEGFR-3 (T), VEGFR-3 expression in tumour cells; VEGFR-3 (EC), VEGFR-3 expression in endothelial cells. 
Table 2 Correlation between VEGF-C and VEGFR-2 expression 
Expression of  No. of cases No. (%) of cases  P value No. (%) of cases   P value 
VEGF-C with strong positive  with positive
VEGFR-2 (T) VEGFR-2 (EC)
Positive 24 17 (70.8%) 0.016 19 (79.1%) 0.476 
Negative 38 15 (39.4%) 27 (71.0%) 
VEGFR-2 (T), VEGFR-2 expression in tumour cells; VEGFR-2 (EC), VEGFR-2 expression in endothelial cells. 
A B
C Dwithout lymphatic invasion (P < 0.05). The VEGF-C expression
was also significantly associated with gender and pathological
stage (both P < 0.05) (Table 3). 
Correlations of clinicopathological and biological
factors with survival 
Figure 5 shows the survival of patients according to the VEGF-C
status. Patients with VEGF-C expression had significantly poorer
outcomes compared to those without (P < 0.05). From multivariate
analysis, VEGFR-2 expression in endothelial cells, T factor and N
factor retained independent negative prognostic impact on overall
survival (Table 4). 
DISCUSSION 
The findings of the current study demonstrated the positive associ-
ation of VEGF-C expression with both lymph node metastasis and
lymphatic invasion in lung cancer. In addition, a significant posi-
tive correlation was clearly found between VEGF-C expression in
cancer cells and VEGFR-3 expression in endothelial cells. A posi-
tive association of VEGF-C expression with lymph node metas-
tasis has been reported in gastric cancer, prostatic cancer, lung
adenocarcinoma, and colorectal cancer (Tsurusaki et al, 1999;
Yonemura et al, 1999; Akagi et al, 2000; Niki et al, 2000). A
significant correlation between VEGF-C and VEGFR-3 has also
been found in malignant mesothelioma and gastric cancer (Ohta
et al, 1999; Yonemura et al, 1999). Our results indicated the possi-
bility that VEGF-C produced in lung cancer cells modulates
lymphatic metastasis through its receptor, VEGFR-3, in endo-
thelial cells. 
To our knowledge, this is the first report that described the prog-
nostic aspect of VEGF-C expression in lung cancer. The lung
cancer patients with VEGF-C expression had significantly poorer
outcomes compared to those without it. Although we could find no
prognostic independency in VEGF-C and VEGFR-3, the VEGFR-
2 expression in endothelial cells retained significance. Since
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Table 3 Correlation between VEGF-C expression and clinicopathological factors 
Factors No. of cases Case no. (%)  P value 
of VEGF-C positive
Sex 
Male 45 21 (46.6) 0.036 
Female 17 3 (17.6) 
Age 
≤ 65 24 8 (33.3) 0.489 
> 65 38 16 (42.1) 
Histology 
Adenocarcinoma 36 9 (25.0) 0.320 
Squamous cell carcinoma 30 12 (60.0) 
Adenosquamous cell carcinoma 2 2 (100.0) 
Large cell carcinoma 4 1 (25.0) 
Histopathological grading 
Well differentiated 21 6 (28.5) 0.059 
Moderately differentiated 21 8 (38.0) 
Poorly differentiated 15 8 (53.3) 
T factor 
T1 22 7 (31.8) 0.117 
T2, 3, 4 40 21 (52.5) 
N factor 
Positive 25 14 (56.0) 0.021 
Negative 37 10 (27.0) 
Ly invasion 
Positive 24 14 (58.3) 0.011 
Negative 38 10 (26.3) 
v invasion 
Positive 20 9 (45.0) 0.480 
Negative 42 15 (35.7) 
Stage 
I, II 25 9 (36.0) 0.718 
III, IV 37 15 (40.5) 
125 kDa
12345
Figure 4 Western blot analysis of VEGFR-3 expression in lung cancer cell
lines. Lane 1, PC-3; Lane 2, PC-8; Lane 3, PC-10; Lane 4, PC-14; Lane 5,
QG-56 VEGFR-2, which is a receptor for VEGF, VEGF-C, VEGF-D and
VEGF-E, is known to also act as the main regulator of endothelial
cell proliferation and migration (Waltenberger et al, 1994; Joukov
et al, 1996; Ferrara and Davis-Smyth 1997; Achen et al, 1998;
Meyer et al, 1999), we speculate that VEGFR-2 plays a key role in
tumour angiogenesis and tumour progression/development in lung
cancer. 
It is notable that our immunohistochemical study showed posi-
tive VEGFR stainings not only in endothelial cells but also in
cancer cells. Both VEGFR-1 and VEGFR-2 expressions have been
observed in breast cancer, ovarian cancer, prostatic cancer and
melanoma in addition to lung cancer (Gitay-Goren et al, 1993;
Boocock et al, 1995; Lu and Brodie, 1996; Decaussin et al, 1999;
Ferrer et al, 1999; Speirs and Atkin 1999; Xie et al, 1999). On the
other hand, although the existence of VEGFR-3 expression in
cancer cells has been reported in malignant mesothelioma,
Kaposi’s sarcoma, vascular tumour and melanoma (Pajusola et al,
1992; Jussila et al, 1998; Lymboussaki et al, 1998; Ohta et al,
1999), there has been no report on VEGFR-3 expression within
lung cancer cells. Our results demonstrated here seem to
strengthen the notion that lung cancer cells express VEGFR-3.
Considering the positive association found between VEGF-C
expression in lung cancer cells and VEGFR-2/VEGFR-3 stainings
in cancer cells, the role of VEGF-C may encompass the tumour
growth regulation in both paracrine and autocrine fashion.
Although the prognostic impact of VEGFRs expression within
cancer cells was not clear in this study, examination of the activa-
tion status through tyrosin phosphokinase is required to further
elucidate the roles of VEGFRs in lung cancer cells. 
In conclusion, this study enlightens the evidence that VEGF-C
expression within cancer cells and VEGFR-3 expression within
endothelial cells are of influence on the lymphatic metastasis
in non-small cell lung cancer. Further analysis concerning
lymphangiogeneis within tumour should be a promising way to
understand the mechanism underlying the lymphatic metastasis in
non-small cell lung cancer. 
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Table 4 Results of Cox hazard model analysis of prognostic factors
(multivariate)
Parameters c2 p value 95%  CI
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N0 vs. N1–3 9.07 0.003  2.33–54.60
Stage I, II vs. III, IV 2.58 0.108 0.05–1.34
Figure 5 Kaplan–Meier survival plots for lung cancers subdivided according
to the VEGF-C expression. The difference in survival between the positive
group (closed circle) and negative group (open circle) was significant 
(* P < 0.05) 
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